Please login to the form below

Not currently logged in
Email:
Password:

Besponsa

This page shows the latest Besponsa news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

NICE changes its mind on Pfizer’s Besponsa. England’s cost effectiveness watchdog NICE has issued a final appraisal determination recommending Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults ... Following approval in Scotland in

Latest news

  • NICE to look again at Pfizer’s Besponsa after appeal NICE to look again at Pfizer’s Besponsa after appeal

    Pfizer argued that Besponsa treatment more than doubled complete remission rates and made it more likely that patients could go on to receive a stem cell transplant. ... UK practice, however, would largely consist of using [Besponsa] as a step to enable

  • FDA clears Pfizer's leukaemia drug Besponsa FDA clears Pfizer's leukaemia drug Besponsa

    Pfizer has bagged US approval for Besponsa - its treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - two months after it got the go-ahead in ... Besponsa has been approved with a boxed warning for

  • NICE set to reject Pfizer's leukaemia drug Besponsa NICE set to reject Pfizer's leukaemia drug Besponsa

    The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa (inotuzumab ozogamicin). ... For its part Pfizer pointed to the INO-VATE trial, which showed Besponsa more than doubled complete

  • NICE rejects Pfizer's antibody drug for leukaemia NICE rejects Pfizer's antibody drug for leukaemia

    The National Institute for Health and Care Excellence (NICE) has turned down Pfizer’s leukaemia drug Besponsa in draft guidance. ... Pfizer estimates that 117 patients would be eligible for treatment with Besponsa in its first year if it were

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    In other news from the CHMP meeting, Pfizer picked up a positive opinion for Besponsa (inotuzumab ozogamicin) as a single-agent treatment for adults with relapsed or refractory CD22-positive

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics